Gurevičius, Romualdas
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based studyItem type:Publication, research article[2022][S1][M004][9] ;Tomic, Dunya ;Morton, Jedidiah I ;Chen, Lei ;Salim, Agus ;Gregg, Edward W ;Pavkov, Meda E. ;Arffman, Martti ;Balicer, Ran ;Baviera, Marta ;Boersma-van Dam, Elise ;Brinks, Ralph ;Carstensen, Bendix ;Chan, Juliana C.N. ;Cheng, Yiling J. ;Fosse-Edorh, Sandrine ;Fuentes, Sonsoles ;Gardiner, Hélène ;Gulseth, Hanne L; ;Ha, Kyoung Hwa ;Hoyer, Annika ;Jermendy, György ;Kautzky-Willer, Alexandra ;Keskimäki, Ilmo ;Kim, Dae Jung ;Kiss, Zoltán ;Klimek, Peter ;Leventer-Roberts, Maya ;Lin, Chun-Yi ;Lopez-Doriga Ruiz, Paz ;Luk, Andrea O Y ;Ma, Stefan ;Mata-Cases, Manel ;Mauricio, Dídac ;McGurnaghan, Stuart ;Imamura, Tomoaki ;Paul, Sanjoy K ;Peeters, Anna ;Pildava, Santa ;Porath, Avi ;Robitaille, Cynthia ;Roncaglioni, Maria Carla ;Sugiyama, Takehiro ;Wang, Kang-Ling ;Wild, Sarah H. ;Yekutiel, Naama ;Shaw, Jonathan E.Magliano, Dianna J.Lancet. Diabetes and Endocrinology. [New York] : Elsevier Science, 2022, vol. 10, iss. 11., p. 795-803Background: Diabetes is a major public health issue. Because lifetime risk, life expectancy, and years of life lost are meaningful metrics for clinical decision making, we aimed to estimate these measures for type 2 diabetes in the high-income setting. Methods: For this multinational, population-based study, we sourced data from 24 databases for 23 jurisdictions (either whole countries or regions of a country): Australia; Austria; Canada; Denmark; Finland; France; Germany; Hong Kong; Hungary; Israel; Italy; Japan; Latvia; Lithuania; the Netherlands; Norway; Scotland; Singapore; South Korea; Spain; Taiwan; the UK; and the USA. Our main outcomes were lifetime risk of type 2 diabetes, life expectancy in people with and without type 2 diabetes, and years of life lost to type 2 diabetes. We modelled the incidence and mortality of type 2 diabetes in people with and without type 2 diabetes in sex-stratified, age-adjusted, and calendar year-adjusted Poisson models for each jurisdiction. Using incidence and mortality, we constructed life tables for people of both sexes aged 20–100 years for each jurisdiction and at two timepoints 5 years apart in the period 2005–19 where possible. Life expectancy from a given age was computed as the area under the survival curves and lifetime lost was calculated as the difference between the expected lifetime of people with versus without type 2 diabetes at a given age. Lifetime risk was calculated as the proportion of each cohort who developed type 2 diabetes between the ages of 20 years and 100 years. We estimated 95% CIs using parametric bootstrapping. Findings: Across all study cohorts from the 23 jurisdictions (total person-years 1 577 234 194), there were 5 119 585 incident cases of type 2 diabetes, 4 007 064 deaths in those with type 2 diabetes, and 11 854 043 deaths in those without type 2 diabetes. The lifetime risk of type 2 diabetes ranged from 16·3% (95% CI 15·6–17·0) for Scottish women to 59·6% (58·5–60·8) for Singaporean men. Lifetime risk declined with time in 11 of the 15 jurisdictions for which two timepoints were studied. Among people with type 2 diabetes, the highest life expectancies were found for both sexes in Japan in 2017–18, where life expectancy at age 20 years was 59·2 years (95% CI 59·2–59·3) for men and 64·1 years (64·0–64·2) for women. The lowest life expectancy at age 20 years with type 2 diabetes was observed in 2013–14 in Lithuania (43·7 years [42·7–44·6]) for men and in 2010–11 in Latvia (54·2 years [53·4–54·9]) for women. Life expectancy in people with type 2 diabetes increased with time for both sexes in all jurisdictions, except for Spain and Scotland. The life expectancy gap between those with and without type 2 diabetes declined substantially in Latvia from 2010–11 to 2015–16 and in the USA from 2009–10 to 2014–15. Years of life lost to type 2 diabetes ranged from 2·5 years (Latvia; 2015–16) to 12·9 years (Israel Clalit Health Services; 2015–16) for 20-year-old men and from 3·1 years (Finland; 2011–12) to 11·2 years (Israel Clalit Health Services; 2010–11 and 2015–16) for 20-year-old women. With time, the expected number of years of life lost to type 2 diabetes decreased in some jurisdictions and increased in others. The greatest decrease in years of life lost to type 2 diabetes occurred in the USA between 2009–10 and 2014–15 for 20-year-old men (a decrease of 2·7 years). Interpretation: Despite declining lifetime risk and improvements in life expectancy for those with type 2 diabetes in many high-income jurisdictions, the burden of type 2 diabetes remains substantial. Public health strategies might benefit from tailored approaches to continue to improve health outcomes for people with diabetes. Funding: US Centers for Disease Control and Prevention and Diabetes Australia.
4Scopus© Citations 79 Trends in all-cause mortality among people with diagnosed diabetes in high-income settings: a multicountry analysis of aggregate dataItem type:Publication, research article[2022][S1b][M001][8] ;Magliano, Dianna J ;Chen, Lei ;Carstensen, Bendix ;Gregg, Edward W ;Pavkov, Meda E ;Salim, Agus ;Andes, Linda J ;Balicer, Ran ;Baviera, Marta ;Chan, Juliana C N ;Cheng, Yiling J ;Gardiner, Helene ;Gulseth, Hanne L; ;Ha, Kyoung Hwa ;Jermendy, György ;Kim, Dae Jung ;Kiss, Zoltán ;Leventer-Roberts, Maya ;Lin, Chun-Yi ;Luk, Andrea O Y ;Ma, Stefan ;Mata-Cases, Manel ;Mauricio, Didac ;Nichols, Gregory A ;Pildava, Santa ;Porath, Avi ;Read, Stephanie H ;Robitaille, Cynthia ;Roncaglioni, Maria Carla ;Lopez-Doriga Ruiz, Paz ;Wang, Kang-Ling ;Wild, Sarah H ;Yekutiel, NaamaShaw, Jonathan EThe Lancet Diabetes and Endocrinology. [New York] : Elsevier Ltd, 2022, vol. 10, iss. 2., p. 112-119Background: Population-level trends in mortality among people with diabetes are inadequately described. We aimed to examine the magnitude and trends in excess all-cause mortality in people with diabetes. Methods: In this retrospective, multicountry analysis, we collected aggregate data from 19 data sources in 16 high-income countries or jurisdictions (in six data sources in Asia, eight in Europe, one from Australia, and four from North America) for the period from Jan 1, 1995, to Dec 31, 2016, (or a subset of this period) on all-cause mortality in people with diagnosed total or type 2 diabetes. We collected data from administrative sources, health insurance records, registries, and a health survey. We estimated excess mortality using the standardised mortality ratio (SMR). Findings: In our dataset, there were approximately 21 million deaths during 0·5 billion person-years of follow-up among people with diagnosed diabetes. 17 of 19 data sources showed decreases in the age-standardised and sex-standardised mortality in people with diabetes, among which the annual percentage change in mortality ranged from –0·5% (95% CI –0·7 to –0·3) in Hungary to –4·2% (−4·3 to –4·1) in Hong Kong. The largest decreases in mortality were observed in east and southeast Asia, with a change of –4·2% (95% CI –4·3 to –4·1) in Hong Kong, –4·0% (−4·8 to –3·2) in South Korea, –3·5% (−4·0 to –3·0) in Taiwan, and –3·6% (−4·2 to –2·9) in Singapore. The annual estimated change in SMR between people with and without diabetes ranged from –3·0% (95% CI –3·0 to –2·9; US Medicare) to 1·6% (1·4 to 1·7; Lombardy, Italy). Among the 17 data sources with decreasing mortality among people with diabetes, we found a significant SMR increase in five data sources, no significant SMR change in four data sources, and a significant SMR decrease in eight data sources. Interpretation: All-cause mortality in diabetes has decreased in most of the high-income countries we assessed. In eight of 19 data sources analysed, mortality decreased more rapidly in people with diabetes than in those without diabetes. Further longevity gains will require continued improvement in prevention and management of diabetes. Funding: US Centers for Disease Control and Prevention, Diabetes Australia Research Program, and Victoria State Government Operational Infrastructure Support Program
6Scopus© Citations 81 Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settingsItem type:Publication, research article[2021][S1][M001][9] ;Magliano, Dianna J ;Chen, Lei ;Islam, Rakibul M ;Carstensen, Bendix ;Gregg, Edward W ;Pavkov, Meda E ;Andes, Linda J ;Balicer, Ran ;Baviera, Marta ;Boersma-van Dam, Elise ;Booth, Gillian L ;Chan, Juliana C N ;Chua, Yi Xian ;Fosse-Edorh, Sandrine ;Fuentes, Sonsoles ;Gulseth, Hanne L; ;Ha, Kyoung Hwa ;Hird, Thomas R ;Jermendy, György ;Khalangot, Mykola D ;Kim, Dae Jung ;Kiss, Zoltán ;Kravchenko, Victor I ;Leventer-Roberts, Maya ;Lin, Chun-Yi ;Luk, Andrea O Y ;Mata-Cases, Manel ;Mauricio, Didac ;Nichols, Gregory A ;Nielen, Mark M ;Pang, Deanette ;Paul, Sanjoy K ;Pelletier, Catherine ;Pildava, Santa ;Porath, Avi ;Read, Stephanie H ;Roncaglioni, Maria Carla ;Lopez-Doriga Ruiz, Paz ;Shestakova, Marina ;Vikulova, Olga ;Wang, Kang-Ling ;Wild, Sarah H ;Yekutiel, NaamaShaw, Jonathan EThe Lancet Diabetes and Endocrinology. [New York] : Elsevier. Lancet Publishing Group, 2021, vol 9, iss. 4., p. 203-211Background: Diabetes prevalence is increasing in most places in the world, but prevalence is affected by both risk of developing diabetes and survival of those with diabetes. Diabetes incidence is a better metric to understand the trends in population risk of diabetes. Using a multicountry analysis, we aimed to ascertain whether the incidence of clinically diagnosed diabetes has changed over time. Methods: In this multicountry data analysis, we assembled aggregated data describing trends in diagnosed total or type 2 diabetes incidence from 24 population-based data sources in 21 countries or jurisdictions. Data were from administrative sources, health insurance records, registries, and a health survey. We modelled incidence rates with Poisson regression, using age and calendar time (1995–2018) as variables, describing the effects with restricted cubic splines with six knots for age and calendar time. Findings: Our data included about 22 million diabetes diagnoses from 5 billion person-years of follow-up. Data were from 19 high-income and two middle-income countries or jurisdictions. 23 data sources had data from 2010 onwards, among which 19 had a downward or stable trend, with an annual estimated change in incidence ranging from −1·1% to −10·8%. Among the four data sources with an increasing trend from 2010 onwards, the annual estimated change ranged from 0·9% to 5·6%. The findings were robust to sensitivity analyses excluding data sources in which the data quality was lower and were consistent in analyses stratified by different diabetes definitions. Interpretation: The incidence of diagnosed diabetes is stabilising or declining in many high-income countries. The reasons for the declines in the incidence of diagnosed diabetes warrant further investigation with appropriate data sources. Funding: US Centers for Disease Control and Prevention, Diabetes Australia Research Program, and Victoria State Government Operational Infrastructure Support Program.
6Scopus© Citations 158